Efficacy of human papillomavirus (HPV) vaccines promises to control HPV infections. However, HPV vaccination programs may lay bare an ecological niche for non-vaccine HPV types. We evaluated type-replacement by HPV type and vaccination strategy in a community-randomized trial executed in HPV vaccination na€ ıve population. Thirty-three communities were randomized to genderneutral vaccination with AS04-adjuvanted HPV16/18 vaccine (Arm A), HPV vaccination of girls and hepatitis B-virus (HBV) vaccination of boys (Arm B) and gender-neutral HBV vaccination (Arm C). Resident 1992-95 born boys (40,852) and girls (39,420) were invited. 11,662 boys and 20,513 girls were vaccinated with 20-30% and 45-48% coverage, respectively. HPV typing of 11,396 cervicovaginal samples was performed by high throughput PCR. Prevalence ratios (PR) between arms and ranked order of HPV types and odds ratio (OR) for having multiple HPV types in HPV16 or 18/45 positive individuals were calculated. The ranked order of HPV types did not significantly differ between arms or birth cohorts. For the non-HPV vaccinated 1992-1993 birth cohorts increased PR, between the gender-neutral intervention versus control arms for HPV39 (PR A 1.84, 95% CI 1.12-3.02) and HPV51 (PR A 1.56, 95% CI 1.11-2.19) were observed. In the gender-neutral arm, increased clustering between HPV39 and the vaccine-covered HPV types 16 or 18/45 (OR A16 5 5.1, OR A18/45 5 11.4) was observed in the non-HPV vaccinated 1994-1995 birth cohorts. Comparable clustering was seen between HPV51 and HPV16 or HPV18/45 (OR B16 5 4.7, OR B18/45 5 4.3), in the girls-only arm. In conclusion, definitively consistent postvaccination patterns of HPV type-replacement were not observed. Future occurrence of HPV39 and HPV51 warrant investigation.
also against HSIL associated with high-risk HPV types 31 and HPV types 31, 33 and 45, respectively, 3,4 presumably due to cross-neutralizing antibodies induced by the vaccines. 5 A concern has, however, been raised, that following implementation of national HPV vaccination programs the resulting reduction in the prevalence of vaccine-covered HPV types could clear the ecological niche for the non-targeted HPV types. 6 In agreement, type-replacement has been observed in a number of countries following pneumococcal vaccination. 7 However, thus far HPV type-replacement has not been observed at the individual level among HPV vaccinated females with low vaccination coverage in the target population. 8, 9 A prerequisite of HPV type-replacement, that is, competition between HPV types in unvaccinated populations, has not been commonly found. [10] [11] [12] Implementation of national HPV vaccination programs, however, tends to increase prevalence of some non-vaccine covered HPV types suggesting type-replacement. 13 HPV epidemiology of vaccination-na€ ıve populations shows that multiple HPV type infections are rare in women with normal cytology (<3%), 14 very common in women with precancer lesions (15-41%) 15 and again rare in women with HPV-related cervical cancer (<12%). 16 In this study, we explored the possible signs of type-replacement by comparing occurrence of single and multiple HPV types up to five years after community-randomized introduction of gender-neutral or girls-only HPV vaccination with moderate vaccination coverage.
Materials and Methods

Study design
The material was obtained from the community randomized trial of the ASO4-HPV-16/18 vaccine (Cervarix V R ) sponsored by GlaxoSmithKline. 17, 18 Briefly, all 80,272 resident Finnish or Swedish speaking boys and girls as identified using the population register were invited in 33 Finnish communities randomly assigned to one of three study arms ( Fig. 1 ): Arm A was gender-neutral, Arm B was gender-specific and Arm C served as the control arm. In the Arm A, 90% of all the participants in each community were randomly selected to receive Cervarix V R and 10% to receive Engerix-B TM . In the Arm B, 90% of the female study population in each community were randomly selected to receive Cervarix V R and 10% to receive Engerix-B TM , whilst the males all received Engerix-B TM . In the Arm C, all of the participants were given Engerix-B TM . The vaccination status of all the participants in Arm A and all the female participants in Arm B were receiver-blinded. In total, 32,175 participants born in 1992-1995 were initially recruited with informed parental/guardian consent in to the 3 study arms (20,514 females and 11,661 males) at the study baseline, in 2007-2009. Ninety-nine point four percent received three vaccine doses. All females from the study communities, both participants and non-participants were invited to a follow-up visit between the years 2010-2014, at the age of 18.5-19 years, within 3-5 years from vaccination. A total of 14,518 females attended this follow-up visit: 4,922 from Arm A, 5,247 from Arm B and 4,349 from Arm C. During the follow-up session, a self-collected cervicovaginal sample was obtained and a cervical sample was obtained by a study nurse. The participants consented to take part in Chlamydia trachomatis screening, and participants completed a questionnaire about life-style factors, mobility and their sexual health. 17 Residential history data was also available from the population registry. 
Laboratory analysis
The samples collected at the first follow-up visit were analyzed using modified general primer (MGP) PCR followed by matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass spectrometry (MS). 19, 20 The MGP PCR used typespecific consensus primers to replicate specific types of HPV DNA. Every type-specific consensus primer used had a particular molecular weight, which was detected using MALDI-TOF MS to identify the presence of HPV6, 51, 52, 56, 58, 59 and 66) between Arm A and C, and Arm B and C were estimated by log-binomial regression.
As a sensitivity analysis odds ratios (OR with 95% CI) of having another HPV type among those positive for the vaccine HPV types 16 or 18, or the strictly vaccine covered type HPV45 were estimated by arm using those negative for HPV16 or for HPV18/45 as the reference group applying binomial logistic regression. The PR and OR estimates were adjusted for participant mobility, for community-level prevalence of regular smoking and for individual level C. trachomatis status, reflecting the risk-taking behavior. 18 The between-arms relationships of HPV type prevalence ranks were assessed by comparing Spearman's rank correlation coefficients.
In our first impact of vaccination strategies article, 18 herd effects at the follow-up of age 18.5 years were observed to be stronger in the later than earlier age cohorts. Thus, all the above-mentioned estimates were computed separately for 1992-1993 and 1994-1995 cohorts.
Both participants who had migrated from control arm communities to Arm A or B, and those who had migrated from Arm A or B communities to control Arm C, were excluded from the analysis (N 5 92). However, participants moving from Arm A to B (N 5 31), and Arm B to A (N 5 34) were included. Due to the follow-up invitations of non-participants, the HBV vaccinated:unvaccinated ratio was different in Arm C compared with Arm A and Arm B in non-HPV-vaccinated women. The difference was corrected for in the PR and OR estimation ( Fig. 2 and Table 3 ): Twenty-one samples, one eighth of HBV vaccinated Arm C women each, were randomly selected from 44 birth yearcommunity strata. Each sample was joined with all Arm C unvaccinated women. The PR estimate was the mean of 21 random sample-specific estimates. The 95% CIs were estimated by a homogenization-based approach, described in Ref. 18 .
The statistical analyses were conducted using SPSS statistical software version 23.0 (IBM Corp, Armonk, NY) and R statistical software version 3.3.2 with Epi package (version 2.15, The R Foundation; https://www.r-project.org/). The values of trigamma functions for homogenization-based CIs were calculated using SAS 9.4 (SAS Inst. Inc., Cary, NC).
Results
Demographics and behavioral characteristics of the trial arms
Entire 1992-1995 Finnish and Swedish speaking female and male birth cohorts of the 33 randomized communities were invited to the trial on the effectiveness of HPV vaccination strategies ( Fig. 1) . Participation rates at the study baseline and attendance rates to the follow-up visit at study end were equal in the different groups of vaccination participants and attendees of the cytological sampling ( Fig. 1 ).
Demographic and risk-taking behavior characteristics of the study arms revealed no major differences between the HPV vaccinated and non-HPV vaccinated women (Table 1) . However, more non-HPV vaccinated women had 5 or more life-time partners (19.2 and 16.7%) in intervention Arms A and B with gender-neutral and girls-only HPV vaccination, respectively, than in the control Arm C (13.7%) with HBV vaccination. In addition, more non-HPV vaccinated Arm A participants were current smokers (34.2%) in comparison to the non-HPV vaccinated Arm C participants (30.3%) ( Table 1 ). 
HPV PRs in HPV vaccinated and non-HPV vaccinated women
The effect of HPV vaccination in the HPV16/18 vaccinated 1994-1995 birth cohorts extended over five HPV types: 16/ 18/31/33/45 in the PR analysis (Figs. 2a and 2b) . As for the nonvaccine covered HPV types, no major differences in the PRs between the intervention Arms A or B and the control Arm C were observed in the non-HPV16/18 vaccinated women (Figs. 2c and 2d ). Amongst increased PRs there, however, was a pattern of 3 out of 4 significantly increased HPV51 PRs in both vaccinated and non-HPV vaccinated 1992-1993 birth cohorts (Figs. 2a-2c ).
In the 1992-1993 birth cohort the PR between the non-HPV vaccinated participants of the gender-neutral intervention Arm A versus the control Arm C for HPV39 (PR A 1.84, 95% CI 1.12-3.02) was significantly different from unity (Fig. 2c) . In the girls-only intervention Arm B versus the control Arm C PRs for HPV6 (PR B 1.74, 95% CI 1.19-2.56) and for HPV52 (PR B 1.60, 95% CI 1.09-2.36) also were increased (Fig. 2d) . In addition, in the 1992-1993 birth cohorts between the non-HPV vaccinated participants the PRs for HPV33 tended to be increased in both intervention arms (PR A 1.56, 95% CI 0.83-2.93, PR B 1.86, 95% CI 1.05-3.27; Figs. 2c and 2d) .
With the exception of HPV45 (PR A 1.70, 95% CI 1.02-2.82 vs. PR B 0.80, 95% CI 0.42-1.51), no notable discrepancy in the PRs were observed between the intervention Arms A and B, and control Arm C in the 1994-1995 birth cohorts. 
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Multiple infections in HPV vaccinated and non-HPV vaccinated women
The PR observations of note were further elaborated by a sensitivity analysis on clustering of specific HPV types. Clustering of a number of HPV types with the vaccine or vaccine-covered HPV types 16 and HPV18/45 was evaluated as OR of being positive for another HPV type, for HPV16 or HPV18/45 positive versus HPV16 or HPV18/45 negative women. ORs for those HPV types with significantly increased PRs (HPV6/33/39/45/51/52/66) were calculated in HPV vaccinated women (Table 2 ) and non-HPV vaccinated women (Table 3) . We observed occasional, nonsignificant, clustering (Tables 2 and 3 ). Likewise, no consistently increased ORs were observed for HPV6 or HPV52 in the non-HPV vaccinated women or in the HPV vaccinated women (Tables 2 and 3) .
Post vaccination HPV type-distributions by vaccination strategy
To further evaluate the impact of HPV vaccination generated herd effect on the HPV population biology we compared the ranked distribution of non-vaccine covered HPV types in the non-vaccinated female 1992-birth cohort (first vaccinated birth cohort) and 1995-birth cohort (last vaccinated birth cohort). Among both the 1992 and 1995 birth cohorts the correlation coefficients of HPV type distributions between Arms A (gender-neutral vaccination) and C, Arms B (girlsonly vaccination) and C were high (0.79 to 0.95) and statistically indistinguishable (Fig. 3) .
Discussion
Sporadic HPV39 and 51 occurrence but, no patterns suggestive of type-replacement following vaccination with the bivalent HPV16/18 vaccine and up to 20% coverage in boys and 50% coverage in girls were found in our population-based, community-randomized trial.
Despite of HPV16 epidemic documented in Finland in the 1980s and 1990s, 21, 22 the prevalence rates of HPV types are relatively stable with HPV16 dominating. 14, 23 This seemed to be true also for the ranked order of oncogenic HPV type prevalence rates, especially in our control Arm C, devoid of any intervention. We have previously shown significant herd effect against HPV18, 31 and 33 in our community randomized trial. 18 We now used the community randomized trial setting to discover changes in the HPV type specific occurrence in the vaccinated communities (Arm A and Arm B) subject to moderate vaccination coverage. Due to vaccine induced direct and cross-protection, 4 no major differences in PRs between arms or the ranked order of prevalence rates for non-vaccine covered HPV types were observed in non-HPV vaccinated women. With the latter approach, we identified changes on C. trachomatis serotypes over decades due to population movements. 25 In this study, post-vaccination follow-up time may, however, have been too short and the sample size limited, to observe changes in the distribution of nonvaccine oncogenic HPV types.
A recent meta-analysis of 9 studies found slightly increased prevalence rates for HPV types 39 and 52 when comparing pre-and post-vaccination type-distributions. 13 Comparing intervention communities of the gender-neutral and girls-only arms with the non-intervention communities of the control arm was a comparable approach. We found significantly increased HPV39 and HPV51 PRs in the gender-neutral Arm A communities among the 1992-1993 birth cohorts, and found some evidence suggesting increased clustering of HPV39 in HPV16 or HPV18/45 positive women in the gender-neutral intervention communities among the 1994-1995 born. As for HPV51, comparable clustering was observed only in the girls-only arm. The risk of being HPV39 or HPV51 positive among HPV16 or HPV18/45 positive women was adjusted for mobility, smoking and C. trachomatis positivity (a surrogate of risk-taking sexual behavior) but the fact that the observations were not birth cohort or intervention arm specific may not support typereplacement. Furthermore, comparable Arm A specific clustering in the 1994-1995 born women was observed for HPV52 which showed a PR increase in the girls-only Arm B communities and 1992-1993 birth cohort only.
Post-vaccination evidence of type replacement occurring in the clustering of multiple types approach is defined as increased clustering in the intervention arms as compared with the controls arms, as the replacing type gains the competitive advantage over the vaccine protected type. Furthermore, clustering of multiple HPV infections is one of the most sensitive ways of looking for changes in the population biology of HPV types although subject to bias based on behavioral differences (risk-taking factors) and possible correlation of the occurrence of HPV types. 26, 27 Thus, we used it but only as a sensitivity analysis to achieve more insight into a priori hypothesized prevalence rate ratio differences. Additionally, despite the large sample size, the number of some rarer HPV type-specific infections were relatively few in some cases, therefore limiting the power of this analysis. As for HPV16, its unique clearance characteristics make it difficult to compare the different HPV specific clustering observations. 1 Taken together findings from the PR and clustering analyses were not definitively consistent for any HPV type.
Finally, technical unmasking of HPV52 DNA amongst a number of other HPV type DNAs following removal of, for example, HPV16 DNA by vaccination has been described as one potential bias of surveillance studies provided the PCR methodology suffers from the "unmasking" phenomenon. 26, 28 Thus, it is possible that following HPV vaccination the increased prevalence of non-vaccine HPV types are not caused by type replacement but rather by unmasking. Concerning oncogenic HPV types our MALDITOF PCR, however, does not suffer from such problems. 20 Previous studies among non-vaccinated population samples have concluded that HPV type co-infections occur at random in normal cytology, in cervical pre-cancer and in cancer lesion patients. 12, [28] [29] [30] [31] [32] [33] [34] [35] [36] Indeed, if significant clustering of HPV types was observed it was regarded as a bias stemming from the unspecific genotyping of different HPV types. 28, 29 Taken together, and in agreement with the previous studies, despite of sporadic clustering of some high risk HPV types in HPV16 or HPV18/45 positive women no definitively consistent patterns suggestive of type-replacement with non-vaccine HPV types were observed at the population level approximately up to 5 years post vaccination in this real-life community-randomized trial with up to 50% vaccination coverage by community.
In conclusion, our vaccination coverage has been high enough to observe vaccine efficacy and herd effect of HPV vaccination on the occurrence of HPV types, other than HPV16. 18 As for all other HPV types, the study probably had ample power to study type-replacement under the selective pressure from different vaccination strategies. No conclusive signs of type-replacement were observed, but HPV39 and HPV51 occurrence warrants further investigation. 
